SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending following its Q4 earnings, where an adjusted EBITDA miss and persistent scrutiny over its accounting practices and reliance on loan sales have intensified bearish sentiment. The community is sharply divided, with many calling it a 'scam' while others anticipate potential short squeezes or buying activity on the dip amid high volatility.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart's recent Q4 earnings beat expectations for EPS and revenue, but its cautious forward guidance has ignited debate; many worry about its high valuation in a potentially softening consumer environment, while others highlight strong e-commerce growth, AI investments, and a substantial share repurchase program as reasons to buy the dip.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending following its recent earnings report, which showcased significant revenue and user growth, yet a continued net loss. The discussion is highly polarized, with some investors highlighting potential tailwinds from proposed credit card interest rate caps and major partnerships, while others remain concerned about unprofitability, ongoing securities lawsuits, and the stock's substantial post-IPO decline.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing significant momentum after its ANKTIVA bladder cancer therapy received European Commission authorization, sparking widespread community enthusiasm for its global expansion and broader therapeutic potential, amid mounting speculation of a short squeeze.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma (FIG) is rallying after significantly exceeding Q4 earnings expectations and issuing strong 2026 revenue guidance, buoyed by accelerating AI monetization and a new partnership with Anthropic to integrate AI-generated code into its design platform. While many investors are bullish, anticipating a potential short squeeze, skepticism remains among those wary of the broader "SaaSpocalypse" narrative and concerns that strong performance might fade.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending amidst reports of a significant Meta/Nvidia deal, positioning it as a major beneficiary of massive AI infrastructure spending. The community is fiercely debating the stock's extreme undervaluation and growth prospects against persistent concerns over margin pressures and perceived market manipulation.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending as shares surged following its latest earnings report, which, despite mixed financials, highlighted strong Gross Order Volume and strategic investments in growth and AI partnerships. However, community sentiment remains split, with some celebrating its long-term potential and insider confidence, while others question its high valuation and the sustainability of consumer demand amidst broader economic pressures and regulatory scrutiny.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals trends following recent earnings that revealed strong Rezdiffra sales, which the community hails as a blockbuster for MASH treatment. Investors are actively debating the company's strategic licensing of new programs, with some viewing it as an aggressive move to dominate the MASH market while others express concerns about expenses and a focus on profitability, intensifying ongoing buyout speculation.

Etsy, Inc. engages in the operation of an online marketplace. It offers handmade products such as shoes, clothing, bags, and accessories. It operates through the following segments: Etsy, Reverb, and Depop. The company was founded in 2005 and is headquartered in New York, NY.

Etsy Inc

Etsy is trending following news of selling its Depop fashion resale platform to eBay for $1.2 billion, providing a significant cash infusion and prompting a sharp stock increase. The community is actively discussing the immediate surge and Etsy's renewed focus on its core business, though some express skepticism regarding the sale at a loss and broader market conditions.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as investors react to its recent robust earnings, highlighting strong cash reserves and broader bullish fundamentals for precious metals, even amid community discussion about potential market manipulation hindering the stock's immediate appreciation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crescent Biopharma (NASDAQ:CBIO) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a report on Saturday...

Crescent Biopharma (NASDAQ:CBIO) Upgraded by Guggenheim to Strong-Buy Rating

Guggenheim upgraded Crescent Biopharma to a "strong-buy" rating and set a $35.00 price objective for the company in a research note on Wednesday...

Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

Crescent Biopharma (NASDAQ:CBIO) Share Price Crosses Above 200 Day Moving Average - Here's Why...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Brokerages

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have been given a consensus recommendation of "Buy" by the seven brokerages that are currently covering the company, MarketBeat.com...

Braidwell LP Invests $4.22 Million in Crescent Biopharma, Inc. $CBIO

Braidwell LP acquired a new stake in Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange...

BVF Inc. IL Makes New Investment in Crescent Biopharma, Inc. $CBIO

BVF Inc. IL purchased a new stake in Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and...

Fairmount Funds Management Llc Purchases 1,360,000 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) Director Fairmount Funds Management Llc bought 1,360,000 shares of the stock in a transaction on Thursday, December 4th. The shares were...

Crescent Biopharma (NASDAQ:CBIO) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Crescent Biopharma is partnering with the Chinese firm Kelun-Biotech to expand its oncology drug pipeline and accelerate its combination strategy.&nbsp;</li><li>The company also announced a $185 million private placement, expected to close around December 8.</li><li>Stocktwits retail sentiment for the stock was ‘extremely bullish’.</li></ul><a href="https://stocktwits.com/symbol/CBIO">Crescent Biopharma (CBIO)</a> announced a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co. to expand its pipeline of oncology drugs and speed up its combination strategy. The company also announced a $185 million private placement, expected to close around December 8.Shares of Crescent were up over 40% in pre-market trading.The company said it has three distinct programs that are expected to enter the clinic in 2026. In addition, the private financing will boost its cash runway.“We’re excited to share the tremendous progress we’ve made executing on our strategy of building a robust portfolio of next-generation oncology therapeutics," said Joshua Brumm, chief executive officer of Crescent.<h2 class="st-heading-2">Partnership Details</h2>The deal will allow Crescent exclusive rights to research, develop, and commercialize SKB105 (also known as CR-003) in the United States, Europe, and all markets excluding Greater China. This is an integrin beta-6 (ITGB6)-directed antibody-drug conjugate (ADC) with a topoisomerase payload.Meanwhile, Kelun-Biotech will obtain exclusive rights to research, develop, and commercialize CR-001 in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The drug is Crescent’s bispecific antibody that the company says has the potential to be foundational in immuno-oncology.Both Crescent and Kelun-Biotech will retain the right to independently develop CR-001 in combination with proprietary ADC pipeline assets.“CR-001, our PD-1 x VEGF bispecific antibody, has the potential to be a foundational immuno-oncology backbone and the partnership we announced with Kelun-Biotech today has enhanced our pipeline of ADCs and accelerated our efforts to deliver potentially best-in-class novel combination therapies,” said Brumm.<h2 class="st-heading-2">Retail Reaction</h2>Stocktwits retail sentiment for the stock changed from ‘neutral’ to ‘extremely bullish’ while message volume jumped to ‘extremely high’.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_5_01_28_PM_png_71929a932d.webp" alt="Stocktwits retail sentiment for the stock is ‘extremely bullish’ while message volume remained ‘extremely high’."> One user noted they were ‘bullish’ on the stock, adding “In with a starter!”<stembedurl>https://stocktwits.com/KuruHabesha/message/638133096</stembedurl>Another said that the stock was long forgotten in their portfolio.<stembedurl>https://stocktwits.com/walkingprinter/message/638132752</stembedurl>Shares of Crescent Biopharma were down about 47% year-to-date but have gained almost 8% in the last month.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/why-tigr-stock-rose-premarket-trade-today/cLILDuARESm">Here’s Why TIGR Stock Rose In Premarket Today – And Retail Traders Think The Rally’s Just Starting</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today

Crescent Biopharma announced a strategic partnership with the Chinese firm Sichuan Kelun-Biotech Biopharmaceutical Co. to fast-track its global oncology pipeline. 

Equity

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) has been given a consensus recommendation of "Buy" by the seven ratings firms that are currently covering the firm, Marketbeat.com reports...

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Crescent Biopharma Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $WMT earnings on Thursday?

Current Price	$9.72
Prev Close	$9.33
Open	$9.24
Dividend Yield	0.00%
50-Day Moving Average	$11.59
Beta	0.65
Avg. Volume	166,271.85
PE Ratio	-0.44

52-Week High	$31.14
52-Week Low	$8.72
Market Capitalization	$267.85M
EPS (Annual)	-$58.75
Price to Book	1.20
Revenue Per Employee	$0.00

CBIO
Crescent Biopharma Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CBIO News

CBIOCrescent Biopharma Inc.